ArticleCancer cell international2026
Invasiveness-related microRNA expression in glioma: associations with clinical outcomes, tumor burden, and health-related quality of life.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGliomas are heterogeneous brain tumors that are often studied with a focus on survival rates. However, clinical outcomes include not only survival but also functional status and health-related quality of life (HRQoL). While microRNAs (miRNAs) are recognized as diagnostic and prognostic biomarkers, the aim of this study was to link invasiveness-related miRNA profiles with HRQoL to support individualized treatment strategies for glioma patients.
methodsThe expression of 17 invasiveness-related miRNAs (miR-7, miR-10b, miR-17, miR-21, miR-30b, miR-34a, miR-93, miR-139, miR-143, miR-148a, miR-181a, miR-181b, miR-181d, miR-193a, miR-200c, miR-221, and miR-335) was analyzed via quantitative real-time polymerase chain reaction. miRNA associations with 9 HRQoL parameters (functional status, overall QoL, tumor-related symptoms, depression, cumulative learning, delayed recall, psychomotor speed, executive functions, and verbal fluency), patient clinical characteristics (sex, age, tumor grade, IDH and MGMT status), and tumor characteristics (volume, level of edema, and hemisphere) were assessed via the Mann–Whitney U test, Spearman correlation, Kaplan–Meier and Cox regression analyses. Decision tree modeling was applied to identify key miRNAs that predict individual HRQoL features.
resultsmiR-21 demonstrated the strongest clinical relevance, showing statistically significant associations with five key parameters: patient age, tumor grade, IDH mutation status, tumor volume, and hemisphere. Survival analysis revealed that the higher expression of miR-10b, miR-21, miR-148a, miR-193a, miR-200c, miR-221, and miR-335 was significantly associated with shorter overall survival, while miR-139 – with improved survival. Among the HRQoL domains, overall QoL exhibited the greatest number of miRNA correlations and miR-139 demonstrated the greatest number of significant associations across HRQoL parameters. miR-181a appeared in the greatest number of predictive models (for functional status, overall QoL, and depression), where the functional status model, based on Karnofsky performance status scores, showed excellent performance (specificity = 100%, overall accuracy = 77,6%).
conclusionsThis study highlights the potential of invasiveness-related miRNAs as dual-purpose biomarkers that are informative not only for glioma prognosis but also for predicting HRQoL outcomes. By integrating molecular profiling with patient-centered metrics, our findings support the development of more personalized, QoL-aware care strategies for glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.